Plain-English translation of NCT06255782 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is one of the first times this treatment has been tested in people.
This trial is testing ECUR-506, a new gene therapy designed to treat newborns with a rare genetic condition that prevents their bodies from removing ammonia—a toxic waste product. The medication works by delivering a working copy of the faulty gene directly into the baby's cells, so their liver can start removing ammonia properly. Researchers will give babies a single intravenous infusion and monitor them closely to see if the treatment is safe and effective.
Babies born with this metabolic disorder face life-threatening ammonia buildup in their blood within the first days of life, which can cause severe brain damage. Current treatments help manage symptoms but don't fix the root problem, so doctors are testing this medication as a potential one-time cure that could work at the genetic level.
Your baby will receive a single intravenous infusion of the medication, delivered through a vein into the bloodstream. After that one treatment, your family will return for follow-up visits and tests to monitor how well the medication is working and check for any side effects. The study will track your baby's ammonia levels, liver function, and overall health over time to see if this one-time gene therapy helps reduce or eliminate the need for strict dietary and medication management.
AI-generated summary from trial data · Aug 29, 2026 · Not medical advice
United States